On Thursday, Shares of JPMorgan Chase & Co. (NYSE:JPM), lost -0.82% to $ 67.48.
JPMorgan Chase & Co., declared that in accordance with the terms of the outstanding warrants to purchase common stock of JPMorgan Chase (NYSE: JPM/WS), the warrant Exercise Price will be reduced to $42.325 per share from $42.363 per share, effective as of the close of business on July 6, 2015.
This adjustment resulted from the declaration by the Board of Directors of JPMorgan Chase on May 19, 2015 of a quarterly dividend of $0.44 per share on the outstanding shares of the Firm’s common stock. The dividend is payable on July 31, 2015, to stockholders of record at the close of business on July 6, 2015. This dividend declaration did not result in a change in the Warrant Share Number.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), declined -0.31% to $ 67.48, during its last trading session.
Bristol-Myers Squibb Co, declared that Bristol-Myers Squibb (BMY), a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center® at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster. As the anchor tenant in Alexandria’s newest ground-up development at 100 Binney Street, Bristol-Myers Squibb will lease 208,000 rentable square feet (RSF) in a world-class, highly sustainable office/laboratory facility that has a total of 431,500 RSF. The project will start construction in July 2015 and is predictable to be delivered in the fourth quarter of 2017.
The decision by Bristol-Myers Squibb to locate its state-of-the-art research facility in the Cambridge Kendall Square innovation cluster affirms Alexandria Center at Kendall Square’s reputation as one of the world’s most desirable locations for life science recruitment, innovation, and collaboration.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Metlife Inc (NYSE:MET), ended its last trade with -0.55% loss, and close at $ 56.16.
The final congressional approval of TPA provides a path forward for the pending Trans Pacific Partnership (TPP), which is critical to U.S. companies doing business in the Asia-Pacific region. The trade agreements facilitated by TPA will encourage access to the financial protection and other life insurance products that are in growing demand globally.
“Passage of TPA equips our nation’s trade negotiators and Congress to collaborate on trade agreements that will ensure U.S. companies can compete on a level playing field in markets around the world,” said MetLife Chairman, President and CEO Steven A. Kandarian. “I congratulate Congress for taking this important step, which will assist U.S. companies grow in an increasingly global economy.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
